Actively Recruiting
Mechanisms of Maternal Immune Tolerance in Early Pregnancy
Led by University Hospital, Basel, Switzerland · Updated on 2026-03-04
100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying how the maternal immune system adapts to support a healthy pregnancy during the first trimester. This observational study focuses on women undergoing in vitro fertilization (IVF) to understand the immune cell profiles and functional pathways that allow the mother's body to tolerate the fetus and prevent complications like miscarriage. The goal is to identify key immunological factors that contribute to successful implantation and early gestation. Participants will have blood samples collected at several specific times: before embryo transfer, during the first trimester (around weeks 6-7), and after a miscarriage if it occurs. These samples will be analyzed using advanced tests to examine immune cell types, their activation, and cytokine patterns. The study tracks changes over time to capture how immune regulation evolves from before conception through early pregnancy or implantation failure. During the study, participants will provide blood samples and may undergo detailed immune cell and molecular analyses, including single-cell RNA sequencing and receptor profiling of T and B cells. The main outcome measured is the immune cell composition in peripheral blood at different pregnancy stages. Researchers will monitor these immune changes to better understand maternal tolerance mechanisms, with study participation lasting through the first trimester or after miscarriage up to 12 weeks of gestation.
CONDITIONS
Brief Title
Mechanisms of Maternal Immune Tolerance in Early Pregnancy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women undergoing pregnancies or failed implantations conceived through IVF/ICSI treatment
- Age 18 years or older
- Signed written informed consent
You will not qualify if you...
- Maternal infections such as HIV, Hepatitis B, Hepatitis C, or Syphilis
- Use of immunosuppressive medications at the time of blood sample collection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to the day of embryo transfer
Participants undergo blood sampling before embryo transfer to analyze immune cell composition and molecular signatures related to pregnancy.
1 visit (in-person)
Duration - Up to 12 weeks of gestation
Participants have blood samples collected during early pregnancy and after miscarriage to track immune changes through the first trimester.
Approximately 3 visits (in-person) including week 6-7 of pregnancy and following implantation failure or miscarriage
Trial Site Locations
Total: 1 location
1
University Hospital Basel
Basel, Switzerland, 4031
Actively Recruiting
Research Team
U
Ursula Gobrecht-Keller, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here